Methionine adenosyltransferase (MAT) is a key enzyme in transmethylation, transsulfuration, and the biosynthesis of polyamines. Genetic deficiency of ea/,B-MAT causes isolated persistent hypermethioninemia and, in some cases, unusual breath odor or neural demyelination. However, the molecular mechanism(s) underlying this deficiency has not been clearly defined. In this study, we characterized the human a/,B-MAT transcription unit and identified several mutations in the gene of patients with enzymatically confirmed diagnosis of MAT deficiency. Site-directed mutagenesis and transient expression assays demonstrated that these mutations partially inactivate MAT activity. These results establish the molecular basis of this disorder and allow for the development of DNA-based methodologies to investigate and diagnose hypermethioninemic individuals suspected of having abnormalities at this locus.
Introduction
Methionine adenosyltransferase (MAT,' ATP:L-methionine Sadenosyltransferase, EC 2.5.1.6) catalyzes the biosynthesis of S-adenosylmethionine (AdoMet) from methionine and ATP (1) and thus plays a central role in cellular metabolism. AdoMet acts as the methyl donor for most transmethylation reactions, participates in the transsulfuration pathway and, after decarboxylation, serves as a propylamine group donor in the biosynthesis of polyamines (2, 3) . Three forms of MAT (a, /3, and y) have been identified in mammalian tissues (4) (5) (6) (7) (8) . The a and MATs, composed of homotetramers and homodimers, respectively, are expressed primarily in adult liver (6, 9) . Although the a and forms have distinct kinetic properties, no difference is observed in their subunit structures (4) (5) (6) suggesting that both are encoded by the same gene. Southern analysis of genomic DNA using either a human (9) or a mouse (10) MAT cDNA probe further shows that the a//3-MAT is encoded by a single copy gene. The y form is expressed in fetal liver, kidney, brain, and lymphocytes (7, 8) . Sequence comparison of the cDNAs (9) (10) (11) suggests that y-MAT is probably encoded by a separate gene(s).
Hepatic a/,8 MAT deficiency has been positively diagnosed in seven patients by demonstrating reduced MAT activity in liver biopsy specimens (12) (13) (14) (15) . However, clinical and biochemical characteristics have been published on only six patients (12) (13) (14) (15) (16) (17) . These individuals are characterized by isolated persistent hypermethioninemia. Absent are hyperhomocysteinemia, tyrosinemia, or serious liver disease, signs of conditions in which hypermethioninemia is a secondary feature. The plasma methionine concentration in a/,/-MAT-deficient patients can be as high as 1,300 MM, some 35 times above the upper limit of -35 uM in normal adults. In some patients, an unusual breath odor occurs due to the presence of unusually large amounts of dimethylsulfide (17) . Most of these patients have been free of major clinical difficulties (3). When assayed, MAT activity in their erythrocytes, lymphocytes, or fibroblasts has been normal (14, 17, 18) . Routine screening of newborns for hypermethioninemia has identified additional individuals with biochemical abnormalities suggestive of a//3-MAT deficiency (3, 19 A human placenta genomic library in XEMBL-3 (Clontech, Palo Alto, CA) was screened with the phMAT-l cDNA and one genomic clone, hMATG3, which lacks exon I, was obtained and characterized. A fragment of 2.4 kb containing exon I and part of intron 1 of the a/ ,/-MAT gene was isolated by PCR amplification of human genomic DNA using a sense primer containing nucleotides -67 to -50 of the human a //-MAT cDNA, pSHL (9) , and an antisense primer (5 '-ATA-CATGCTGGCCACCTTAGGCTT-3', Ilas) containing sequence within intron 1. Both strands of the cDNA and genomic clones were sequenced, and the genomic sequences were compared to cDNA sequences as a means to identify intron-exon junctions.
MAT-deficient individuals. We have analyzed the a//3-MAT gene of three MAT-deficient patients positively diagnosed as having reduced MAT activities in liver biopsy samples. The defects in patient GI (Caucasian American female) ( 14) and G3 (African American female) ( 14) have been extensively characterized. Genomic DNA preparations from GI and the mother of GI were extracted from the blood samples. The genomic DNA preparation from patient G3 was isolated from cultured skin fibroblasts kindly sent to us by Dr (20) by electrophoresing wild-type and mutant target DNAs side by side through mutation detection enhancement (MDE) nondenaturing gels (AT Biochem, Malvern, PA) following the protocols provided by the manufacturer. To increase sensitivity of SSCP analysis, we also analyzed the amplified fragments on MDE gels containing 5% glycerol. Mutations in the target DNA were visualized by the differential migration of one or both of the mutant strands.
Construction of cr//3-MAT mutants. The pSVLhMAT-ApaI-5' and pSVLhMAT-ApaI-3' fragments were obtained by digestion of pSVLhMAT-l cDNA with XbaI/ApaI and XhoI/ApaI, respectively, and the respective fragments were purified on a low melting agarose gel. The pSVLhMAT-ApaI-5' fragment (containing nucleotides 1-663 of hMAT) was used as template for constructing mutants containing mutations in exons I to VI by site-directed mutagenesis (22) and the pSVLhMAT-ApaI-3' fragment (containing nucleotides 664-1188 of hMAT) for construction mutants containing mutations in exons VI through IX. Each construct was shown to be correct by DNA sequencing.
Expression in COS-] Cells. Wild-type or mutant a/13-MAT cDNAs were transfected into COS-1 cells by the DEAE-dextran/chloroquine method (23) . Mock transfections of COS-1 cultures with the pSVL vector were used as controls. Two independent isolates of each construct were used in quadruplet cultures. After incubation at 370C for 3 d, the transfected cultures were homogenized in 0.3 ml of a buffer containing 0.25 M Tris-HCl, pH 7.4, and 4 mM /3-mercaptoethanol and used for measuring enzyme activity.
MAT was assayed essentially as described (8 
Results
Characterization of the human a/lf-MAT transcription unit.
The hMATG-3 genomic clone, which lacks exon I, was isolated from a human placenta genomic library using a phMAT-l cDNA probe containing nucleotides (Fig. 1 A) . Fig. 1 ) to amplify individually the coding regions contained in exons I through IX and the associated intron-exon junctions. The amplified fragments were analyzed by SSCP (20) to detect mutation-containing fragments.
SSCP analysis on MDE gels in the absence (Fig. 2 A) or presence ( Fig. 2 B) of glycerol revealed the presence of mutations in the a/,/-MAT gene of all three patients, GI, G3, and MG. The mutation in patient GI was not clearly detected by SSCP on regular MDE gels (data not shown). However, this mutation could be identified using MDE gels containing 5% glycerol (Fig. 2 B) . The mutation-containing fragments were subcloned, and five or more subclones of each fragment were sequenced. Sequence data of the defective genes were compared with the normal gene to identify mutations. SSCP analysis (Fig. 2 B) of GI suggests that this patient may be homozygous for a mutation in exon VIII. This analysis also suggests that the mother of GI is heterozygous for the same mutation. Sequence analysis of five exon VIII subclones of patient Gi revealed that all subclones contained a T to G mutation at nucleotide 966 that converts ( Fig. 3) . Four of the seven exon VIII subclones of the mother of GI contained this mutation.
SSCP analysis of patient G3 revealed that the fragments representing exons II, VII, and VIII contained mutations. Sequence analysis revealed that two of the five exon II subclones had a C to A transversion at nucleotide 164 that converts Ala-55 to an Asp (A55D) (Fig. 4) . 3 of the 10 exon VIII subclones had a C to T transition at nucleotide 1070 that converts Pro-357 to a Leu (P357L) (Fig. 4) . Three of the five exon VII subclones had a C to T mutation in the associated intron 7 which may represent sequence polymorphism. Our results suggest that patient G3 is a compound heterozygote with different mutations in each of the two a/,6-MAT alleles.
SSCP analysis of patient MG revealed that the fragments representing exons V (data not shown), VII (Fig. 2 A) , VIII (Fig. 2 A) , and IX (data not shown) contained mutations. Sequence analysis of the subclones indicated that the exon V mutation (a C to T at nucleotide 426) did not change the code for Ala-142, while the exon IX mutation (a T to C at nucleotide 1131) did not change the code for Tyr-377. Two mutations were contained in the exon VII fragment, a G to A transition at nucleotide 870 that did not change the code for Val-290 (data not shown) and a T to C transition at nucleotide 914 (two of the eight subclones) that converts Leu-305 to a Pro (L305P) (Fig. 5) . Two of the five exon VIII subclones contained a T to G transversion at nucleotide 966 that converts Ile-322 to a Met (1322M) (Fig. 5) . Our findings suggest that patient MG is also a compound heterozygote.
The liver biopsy samples of patients GI and G3 had low levels of MAT activity (14) . Although the details of patient MG have not been published, the available data indicate that MAT activity in the liver biopsy sample of this patient was also very low. This suggests that MAT harboring the A55D, L305P, 1322M, or P357L mutation will have reduced enzymatic activity. To further investigate these points, four aY/f3-MAT mutants were constructed, each containing one of the four mutations identified in the patients. All four mutations yielded mutant MAT with low but detectable enzyme activity (Table I) . Northern hybridization analysis of MAT transcripts from transfected cells showed that wild-type and mutant MAT mRNAs were expressed at similar levels (data not shown).
Discussion
We describe for the first time the organization of the human a!l /3i-MAT gene and show it to contain 9 exons and 8 introns. The exons account for the full coding region in the cDNA. Based on gene structure, we characterized several mutations in the gene that account for the decreases in MAT activity in liver biopsy samples of three patients with confirmed MAT deficiency (14) . Two of the patients are compound heterozygotes and one is a homozygote. The 1322M mutation found in the homozygous patient Gi was detected also in the mother of Gi who is heterozygous for this mutation. This mother is clinically well (3). Her plasma methionine concentration is 28 1iM, and her hepatic MAT activity was well within the normal range (14) . Our data suggest that the I322M mutation behaves in a Each of the six patients with confirmed a/,l3-MAT deficiency for whom data are available had some detectable activity of MAT in his or her liver (13) (14) (15) . When tested, these patients had normal y-MAT activities in erythrocytes, cultured skin fibroblasts, and lymphocytes (14, 17, 18) . Since adult liver also expresses low levels of the -y form of MAT (25) , it has been unclear whether the residual MAT activity detected in the livers of these hypermethioninemic patients was due solely to this y-MAT, to residual activity contributed by mutant ae//-MAT, or to some combination thereof. In our transient expression assays of wild-type and mutant ax//3-MAT cDNAs in COS-1 cells, we found that the mutations A55D, L305P, I322M, and P357L only partially inactivated a//3-MAT activity. Thus, the residual hepatic activities detected in these patients are most likely contributed, at least in part, by the mutant ca//l-MAT isozyme and the phenotype of a complete loss of a/fl3-MAT activity remains unknown.
One clinically normal patient retaining hepatic MAT activity equivalent to 7%o of normnal and having greatly elevated plasma methionine concentrations synthesized AdoMet at a rate equal to that of a normal person on a normal methionine intake (17) . However, this patient lacked the normal capacity to catabolize an increased methionine intake (17 
